Taiwanese clinical-stage biotech developing drugs for eye disease, cancer and metabolic disorders.
Taiwanese clinical-stage biotech developing drugs for eye disease, cancer and metabolic disorders.
Has no product sales and funds its trials by raising capital, so progress in late-stage studies decides its value; any future income would come from licensing deals or an approved drug. It is listed on Taiwan's over-the-counter market, the Taipei Exchange.
In one line: A small-cap clinical-stage biotech.
Moat: none (IP / patents). Pre-revenue biotech; value rests on clinical trial outcomes and patent-protected pipeline.
Headquarters: Taipei, Taiwan · Founded: 2016 · Employees: 63
Size Lin BioScience (6696.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $3.98B, the 100th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$162.50 on 18 Nov 2026.
Performance Over six months the shares gained 305.2%, against -2.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 21 in its peer set.
Capital Return on invested capital runs 18.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$0 | NT$0 | NT$0 | NT$0 | NT$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -NT$31.5M | -NT$23.8M | -NT$20.2M | -NT$17.9M | -NT$11.2M |
| EBITDA | -NT$3.94B | -NT$2.83B | -NT$1.44B | -NT$1.08B | -NT$434M |
| Net income | -NT$1.61B | -NT$1.36B | -NT$744M | -NT$687M | -NT$314M |
| Free cash flow | -NT$1.87B | -NT$1.27B | -NT$957M | -NT$1.01B | -NT$382M |
| Capital expenditure | NT$26.9M | NT$8.18M | NT$7.35M | NT$1.97M | NT$22.4M |
| Total debt | n/a | NT$22.8M | NT$34.0M | NT$42.9M | NT$46.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Lin BioScience 6696.TWO | $3.98B | +305% | n/a | n/a | n/a | n/a |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 2.2× | -9.0% |
| Annexon ANNX | $671M | -30% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6696.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.1% | -7.8% | 7th highest of 21 |
| 6-month return | +305.2% | -2.5% | highest of 21 |
| Distance from 52-week high | -21.5% | -34.7% | 3rd highest of 21 |
| ROIC minus cost of capital | -18.2 pp | -11.2 pp | 6th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 4.8× | 25.4% | +15.6% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |